Tozho — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Tozho is a private, pre-clinical biotech firm founded in 2021, based in San Francisco, developing engineered extracellular vesicle (EV) therapies for chronic wound care. Its core technology involves engineering mesenchymal stem cell-derived EVs with CD47 for immune evasion and encapsulating therapeutic enzymes like thymidine phosphorylase to promote angiogenesis and healing. The company is in the early stages, building its platform and advancing towards therapeutic candidates, with a proprietary, scalable manufacturing process aimed at future clinical translation.

Chronic Wound CareRegenerative Medicine

Technology Platform

Proprietary platform for engineering mesenchymal stem cell-derived extracellular vesicles (MSC-EVs). EVs are functionalized with CD47 for immune evasion and stably encapsulate therapeutic enzymes (e.g., thymidine phosphorylase). Supported by a scalable biomanufacturing process using serum-free, microalgal-enhanced culture and a chitin nanoparticle-based isolation method.

Opportunities

The large and growing global chronic wound care market represents a significant opportunity, driven by diabetes and aging populations.

There is a clear unmet need for therapies that offer more effective and durable healing compared to current standards.

Tozho's engineered, cell-free approach could provide a scalable and targeted solution that addresses the inflammatory and ischemic microenvironment of chronic wounds.

Risk Factors

Key risks include the scientific challenge of proving the efficacy and consistent manufacturing of a novel engineered EV therapy, navigating an uncertain regulatory pathway for EV-based products, and competing in a crowded wound care market.

As a pre-revenue startup, the company is also highly dependent on securing ongoing funding to advance its programs.

Competitive Landscape

Tozho competes in the advanced wound care space with large medtech companies offering advanced dressings and devices, as well as biopharma firms developing growth factor and cell-based therapies. Its direct competitors are other biotechs developing EV or exosome-based regenerative therapies, though Tozho aims to differentiate through its specific CD47/thymidine phosphorylase engineering and scalable production platform.

More companies in Drug Delivery & Formulation →More companies in United States →